Trial Profile

A Phase IIb, Randomized, Placebo-Controlled, Dose-Ranging Study of MK5442 in the Treatment of Postmenopausal Women With Osteoporosis.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 11 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Encaleret (Primary)
Indications Postmenopausal osteoporosis
Focus Adverse reactions; Therapeutic Use
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

16 Oct 2012 Results presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.
15 Oct 2012 Primary endpoint 'Lumbar-spine-bone-mineral-density' has not been met.
02 Oct 2012 Actual patient number changed from 384 to 383 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com